Suppr超能文献

无论疾病状态如何,骨髓瘤患者的骨髓中始终存在数量正常的功能性调节性T细胞池。

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.

作者信息

Foglietta Myriam, Castella Barbara, Mariani Sara, Coscia Marta, Godio Laura, Ferracini Riccardo, Ruggeri Marina, Muccio Vittorio, Omedé Paola, Palumbo Antonio, Boccadoro Mario, Massaia Massimo

机构信息

Divisione di Ematologia dell'Università di Torino, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Italy Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), Italy Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino, Italy.

Divisione di Ematologia dell'Università di Torino, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Italy Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), Italy.

出版信息

Haematologica. 2014 Oct;99(10):1605-10. doi: 10.3324/haematol.2014.105866. Epub 2014 Jun 27.

Abstract

Conflicting data have been reported about the frequency and function of regulatory T cells in multiple myeloma. Most studies have investigated peripheral blood rather than bone marrow Tregs and side-by-side comparisons with bone marrow from healthy donors have still not been made. In this study, we show that regulatory T-cells total count, subset distribution, and expression of chemokine receptors are similar in the bone marrow of myeloma patients and healthy donors. Regulatory T cells are not recruited by myeloma cells in the bone marrow and their counts are unaffected by the tumor burden and the disease status. The diversity of T-cell receptor repertoire is highly preserved ensuring broad reactivity and effective suppressor function. Our results indicate that regulatory T cells may not be the main players of immunological tolerance to myeloma cells under base-line conditions, but their fully preserved immune competence may promote their inadvertent activation and blunt T-cell driven anti-myeloma immune interventions even after myeloma cells have successfully been cleared by chemotherapy.

摘要

关于多发性骨髓瘤中调节性T细胞的频率和功能,已有相互矛盾的数据报道。大多数研究调查的是外周血而非骨髓中的调节性T细胞,且尚未与健康供体的骨髓进行并行比较。在本研究中,我们发现骨髓瘤患者骨髓与健康供体骨髓中的调节性T细胞总数、亚群分布及趋化因子受体表达相似。骨髓中的骨髓瘤细胞不会招募调节性T细胞,其数量也不受肿瘤负荷和疾病状态的影响。T细胞受体库的多样性得到高度保留,确保了广泛的反应性和有效的抑制功能。我们的结果表明,在基线条件下,调节性T细胞可能不是对骨髓瘤细胞免疫耐受的主要参与者,但即使骨髓瘤细胞已通过化疗成功清除,其完全保留的免疫能力仍可能促进其意外激活并削弱T细胞驱动的抗骨髓瘤免疫干预。

相似文献

2
Evaluating the role of Tregs in the progression of multiple myeloma.评估调节性 T 细胞在多发性骨髓瘤进展中的作用。
Leuk Lymphoma. 2019 Sep;60(9):2134-2142. doi: 10.1080/10428194.2019.1579324. Epub 2019 Feb 18.
4
Multiple Myeloma and the Immune Microenvironment.多发性骨髓瘤与免疫微环境。
Curr Cancer Drug Targets. 2017;17(9):806-818. doi: 10.2174/1568009617666170214102301.

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验